Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | Director | May 08, 2025 | May 12, 2025 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Operating Officer | October 05, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,480 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 17,100 · Balance 65,480 F1: Reflects a grant of restricted stock units that vests on May 08, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 08, 2026.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.
Moderna, Inc.
Report date October 05, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 125,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 12, 2025 21:33 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-25-000148 · wk-form4_1747085614.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,480 F1 · kind: Reflects a grant of restricted stock units that vests on May 08, 2026. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:28 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 8,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-24-000112 · wk-form4_1715632083.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,380 F1 · kind: Reflects a grant of restricted stock units that vests on May 09, 2025. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:03 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001694665-23-000083 · wk-form4_1686600220.xml · derivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:44 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 9,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-23-000114 · wf-form4_168418346414412.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,903 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2024. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-028352 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $180.00 | $360,000.00 |
DisclosureSEC source: 0001127602-22-028352 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-028352 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 22:00 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-028260 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 22:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $201.70 | $403,400.00 |
DisclosureSEC source: 0001127602-22-028260 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 22:00 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-028260 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-027659 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $195.00 | $390,000.00 |
DisclosureSEC source: 0001127602-22-027659 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-027659 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-027202 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:52 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $172.16 | $344,320.00 |
DisclosureSEC source: 0001127602-22-027202 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-027202 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-026758 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $173.52 | $347,040.00 |
DisclosureSEC source: 0001127602-22-026758 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-026758 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 814 | $173.80 | $141,475.32 |
DisclosureSEC source: 0001127602-22-026546 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,803 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,808 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026546 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,040 Underlying: Common Stock · 1,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026546 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-026392 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $178.01 | $356,020.00 |
DisclosureSEC source: 0001127602-22-026392 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-026392 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-026037 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $184.25 | $368,500.00 |
DisclosureSEC source: 0001127602-22-026037 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-026037 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 192 | $165.59 | $31,793.18 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F5 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 435 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,413 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $162.50 | $325,000.00 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,001 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025490 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-024965 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $154.20 | $308,400.00 |
DisclosureSEC source: 0001127602-22-024965 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,566 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-024965 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-024507 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-024507 · form4.xml · derivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,000 | $150.00 | $600,000.00 |
DisclosureSEC source: 0001127602-22-024507 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,566 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-024507 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-024507 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 839 | $135.81 | $113,946.77 |
DisclosureSEC source: 0001127602-22-021765 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,566 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,807 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021765 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,848 Underlying: Common Stock · 1,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021765 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-021392 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $165.24 | $330,480.00 |
DisclosureSEC source: 0001127602-22-021392 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,598 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-021392 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F5 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $174.09 | $348,180.00 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,598 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.